2024
β-Cell Secretory Capacity Predicts Metabolic Outcomes over 6 Years following Human Islet Transplantation.
Flatt A, Matus A, Gallop R, Markmann E, Dalton-Bakes C, Peleckis A, Liu C, Naji A, Rickels M. β-Cell Secretory Capacity Predicts Metabolic Outcomes over 6 Years following Human Islet Transplantation. Diabetes 2024 PMID: 39630971, DOI: 10.2337/db24-0729.Peer-Reviewed Original ResearchPurified human pancreatic isletsB-cell massB-cell secretory capacityHuman pancreatic isletsSecretory capacityProinsulin secretory ratiosInsulin independenceBeta 2Pancreatic isletsMeasures of graft functionHormone metabolismSecretory ratioIntra-portal infusionOne-year post-transplantGlucose-potentiated arginineType 1 diabetesGraft functionPost-transplantB cellsIsletsMetabolic outcomesFasting glucagonHuman islet transplantationSustained insulin independenceHuman vascularized macrophage-islet organoids to model immune-mediated pancreatic β cell pyroptosis upon viral infection
Yang L, Han Y, Zhang T, Dong X, Ge J, Roy A, Zhu J, Lu T, Vandana J, de Silva N, Robertson C, Xiang J, Pan C, Sun Y, Que J, Evans T, Liu C, Wang W, Naji A, Parker S, Schwartz R, Chen S. Human vascularized macrophage-islet organoids to model immune-mediated pancreatic β cell pyroptosis upon viral infection. Cell Stem Cell 2024, 31: 1612-1629.e8. PMID: 39232561, PMCID: PMC11546835, DOI: 10.1016/j.stem.2024.08.007.Peer-Reviewed Original ResearchProinflammatory macrophagesActivation of proinflammatory macrophagesImmune cell changesCoxsackievirus B4Host damageAccumulation of proinflammatory macrophagesSingle-cell RNA sequencingMulti-omics platformsB cellsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Marker expressionViral infectionViral exposureSyndrome coronavirus 2Endothelial cellsCell changesRNA sequencingSARS-CoV-2MacrophagesCell damageAutopsy samplesOrganoidsPyroptosis
2023
Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies
Zhang Z, Markmann C, Yu M, Agarwal D, Rostami S, Wang W, Liu C, Zhao H, Ochoa T, Parvathaneni K, Xu X, Li E, Gonzalez V, Khadka R, Hoffmann J, Knox J, Scholler J, Marcellus B, Allman D, Fraietta J, Samelson-Jones B, Milone M, Monos D, Garfall A, Naji A, Bhoj V. Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies. Cell Reports Medicine 2023, 4: 101336. PMID: 38118406, PMCID: PMC10772570, DOI: 10.1016/j.xcrm.2023.101336.Peer-Reviewed Original ResearchConceptsChimeric antigen receptorLong-lived plasma cellsB-cell maturation antigenAllo-antibodiesMultiple myelomaB cellsChimeric antigen receptor-T therapyEfficacy of chimeric antigen receptorAllo-transplantationAnti-human leukocyte antigenTarget B cellsMemory B cellsCART-19T therapyMaturation antigenLeukocyte antigenAntigen receptorClinical efficacyMurine modelPlasma cellsClinical evaluationHyperacute rejectionDesensitization approachImmunotherapyTransplantation